This article is more than 5 years old. Information may no longer be current.
Genetic link to bladder cancer risk, mortality observed
Click Here to Manage Email Alerts
Variations in the regulator of G-protein signaling pathway were associated with increases in disease progression and death among certain populations of patients with bladder cancer, study results showed.
The researchers used a case-control series to investigate the role of alterations in the regulator of G-protein signaling pathway in overall bladder cancer risk, recurrence, progression and survival. The investigation included 803 patients and 803 controls.
Ninety-five single nucleotide polymorphisms in 17 regulator of G-protein signaling genes underwent analysis. Researchers hoped to find links to risk, recurrence and progression outcomes in those with nonmuscle-invasive disease and mortality in patients with muscle-invasive disease.
The strongest link to overall risk was observed in reference SNP 10759 (rs10759) on the RGS4 gene. This SNP carried a 0.77-fold reduction in risk with an increasing number of variant alleles (P<.001).
The researchers also evaluated for cumulative effects of SNPs. Findings from that analysis indicated that all five significant SNPs were linked to increases in risk with the number of unfavorable genotypes (OR=4.13; 95% CI, 2.14-7.98).
Eleven SNPs were associated with recurrence in patients with nonmuscle-invasive disease, and 13 were associated with progression in this cohort.
Among patients with muscle-invasive bladder cancer, 10 SNPs were linked to mortality. The most significant of these, rs2344673, when in an additive model, was associated with a decrease in median survival of 13.3 months. By comparison, survival was 81.9 months in those without a variant allele.
Click Here to Manage Email Alerts